Monika Oliver

Dr. Monika Oliver

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2024 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
JSJustin Smith
Justin Smith
VHVarinder Hans
Varinder Hans
EYElaine Yacyshyn
Elaine Yacyshyn
ARAzin Rouhi
Azin Rouhi
MOMonika Oliver
Monika Oliver

Verified
Journal Article
Open access
PDF file
Jeff SzerJeff Szer
Jeff Szer
JPJens Panse
Jens Panse
AKAustin Kulasekararaj
Austin Kulasekararaj
MOMonika Oliver
Monika Oliver
BFBruno Fattizzo
Bruno Fattizzo
RLRégis Peffault de Latour
Régis Peffault de Latour
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, potentially life-threatening haematological disease characterised by chronic complement-mediated haemolysis with multiple clinical consequences that impair quality of life. This post hoc analysis assessed haematological and clinical responses to the first targeted complement C3 inhibitor pegcetacoplan in patients with PNH and impaired bone marrow function in the PEGASUS (NCT03500549) and PRINCE (NCT04085601) studies. For patients with impaired bone marrow function, defined herein as haemoglobin <10 g/dL and absolute neutrophil count <1.5 × 109 cells/L, normalisation of the parameters may be difficult. Indeed, 20% and 43% had normalised haemoglobin in PEGASUS and PRINCE, respectively; 60% and 57% had normalised LDH, and 40% and 29% had normalised fatigue scores. A new set of parameters was applied using changes associated with clinically meaningful improvements, namely an increase in haemoglobin to ≥2 g/dL above baseline, decrease in LDH to ≤1.5× the upper limit of normal, and an increase in fatigue scores to ≥5 points above baseline. With these new parameters, 40% and 71% of PEGASUS and PRINCE patients had improved haemoglobin; 60% and 71% had an improvement in LDH, and 60% and 43% had an improvement in fatigue scores. Thus, even patients with impaired bone marrow function may achieve clinically meaningful improvements with pegcetacoplan.